Peptide lexicon
P021
Peptidomimetic derived from ciliary neurotrophic factor (CNTF), studied in ageing and Alzheimer's models.
| Substance class | Peptide |
|---|---|
| Synonyms | P-21, CNTF-abgeleitetes Peptidomimetikum |
Structure
P021 is based on a CNTF segment extended with an adamantyl-glycine to increase stability and brain penetration.
State of research
Animal studies describe increased BDNF expression, hippocampal neurogenesis and effects on tau pathology and memory.
Status
P021 is not approved as a medicinal product; there are no human data.
Literature
- Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic CompoundBiomolecules, 2022 · PMID 36291618 · DOI 10.3390/biom12101409
- Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's diseaseMol Neurodegener, 2016 · PMID 27400746 · DOI 10.1186/s13024-016-0119-y
- The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathiesExpert Opin Drug Discov, 2023 · PMID 37042028 · DOI 10.1080/17460441.2023.2200245
- Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic DysfunctionJ Alzheimers Dis, 2021 · PMID 34057082 · DOI 10.3233/JAD-201599
- Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in miceAlzheimers Res Ther, 2020 · PMID 32854771 · DOI 10.1186/s13195-020-00666-7
